Compare Amgen, Inc. (AMGN) vs Fidelity National Information Servcs Inc (FIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Fidelity National Information Servcs Inc — how do they compare? Amgen, Inc. trades at $356.94 (market cap $196.12B), while Fidelity National Information Servcs Inc trades at $42.25 (market cap $21.70B). The key difference: Amgen, Inc. is far larger — about 9× Fidelity National Information Servcs Inc's market cap, and Fidelity National Information Servcs Inc pays the higher dividend (4%). Which is the better fit depends on your goals.
| AMGN | FIS | |
|---|---|---|
Market Cap | $196.12B | $21.70B |
Sector | Health | Technology |
52-Week High | $388.16 | $81.94 |
52-Week Low | $271.18 | $37.72 |
Enterprise Value | $241.41B | $42.09B |
Dividend Yield | 2.77% | 4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
FIS trades at $41.98, up 0.89% today, with a bullish technical signal and strong analyst support. Recent earnings beat expectations in Q1 2026, and the company shows improving profitability with a 23.35% net income margin. Positive news includes cloud banking deals with Frankfurt International Bank and First Commerce Bank, reinforcing growth in digital banking services. The stock trades below the consensus price target of $52.57, indicating potential upside.
The outlook for FIS is positive due to strategic cloud expansions and earnings momentum, but risks include high debt levels and macroeconomic pressures on lending. Wall Street consensus is bullish with 58% buy ratings, though investors should monitor debt management and competitive threats in the fintech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →
